* Corresponding Author: Phone 650-225-4577, Email: hanan.emily@gene.com.
Table of Contents:
Page Information S2 Table S1 . Jak family activity of 1-3 S3 Table S2 . Amide modification SAR Table S3 . PDB data used in the generation of Figure 5b 
S4

S5
Experimental procedures for kinetic solubility experiments
S6
Experimental procedures for compounds 1-3 and 11-14 S12 Expression, purification, and crystallization methods for EGFR(TMLR) S12 Expression, purification, and crystallization methods for CDK2
S13
Data collection, structure solution, and refinement methods S14 Table S4 . Crystallographic data reduction and refinement statistics S15 Table S5 . Analytical methods used to determine purity for individual compounds S16 References Compounds were dissolved in DMSO to a concentration of 10 mM. These solutions were diluted into PBS buffer (pH 7.2, composed with NaCl, KCl, Na 2 HPO 4 , and KH 2 PO 4 ) to a final compound concentration of 100 µM, DMSO concentration of 2%, at pH 7.4. The samples were shaken for 24 h at room temperature followed by filtration. LC/CLND was used to determine compound concentration in the filtrate, with the concentration calculated by a caffeine calibration curve and the sample's nitrogen content. An internal standard compound was spiked into each sample for accurate quantification. 
S2
1-Isopropyl-6-[2-(4-methoxypiperidin-1-yl)pyrimidin-4-ylamino]-1,3-dihydroimidazo[4,5-c]pyridin-2-one (12).
To a solution of 25 (400 mg, 1.12 mmol) in dioxane (8 mL) was added 1,1′-carbonyldiimidazole (272 mg, 1.68 mmol) and the reaction mixture heated at 60°C for 6 h. The reaction was stirred at room temperature for 1.5 h and then heated at 50 °C for 18 h. The S11 Purified TMLR kinase domain was mixed in a 2:1 ratio (5µl protein: 2.5µl reservoir containing 10% PEG 10k, 8% ethylene glycol and 0.1M Hepes pH 7.5). Crystals formed after 3 days. The inhibitor-bound complexes of EGFR were prepared by incubating for 18 hours at 19˚C crystals in reservoir solution made 2.5mM in inhibitor (and 2% in DMSO) by addition of 50 mM DMSO stock solution. Crystals were preserved for data collection by passage through reservoir supplemented with 25% glycerol before immersion in liquid nitrogen.
1-isopropyl-N-[2-(4-methoxy-1-piperidyl)pyrimidin-4-yl]-2,3-dihydropyrrolo[3,2-c]pyridin-
6-amine (13).
Expression, purification and crystallization of CDK2
1
The gene encoding human CDK2 was subcloned into the pVL1393 baculovirus expression vector (Pharmingen). Amplified virus stock was used to infect T. ni cells which were then incubated at 28˚C for 3 days for protein production. Cells were harvested by centrifugation and stored at -80 0 C. Frozen cells were thawed and suspended in 25 mM Tris pH 7.2, 25 mM NaCl, 1 mM TCEP and 2.5% glycerol with protease inhibitor tablets (Roche). The suspension was homogenized (Microfluidizer), stirred at 22˚C for 30 minutes, and then clarified by centrifugation at 180,000xg S13 for 1 hour. Supernatant was passed over a QHP 5ml column (GE Healthcare) pre-equilibrated with 25 mM Tris pH 7.2, 25 mM NaCl, 1 mM TCEP and 2.5% glycerol, collecting the flowthrough. The flow-through was passed over a SPHP 5 ml column pre-equilibrated with 25 mM Tris pH 7.2, 25 mM NaCl, 1mM TCEP and 2.5% glycerol (GE Healthcare), again collecting the flow-through. This flow-through was concentrated for injection onto a Superdex S200 size exclusion column (GE Healthcare) pre-equilibrated with 20 mM Hepes pH 7.2, 150 mM NaCL, 1mM TCEP and 1 mM EDTA. The monomeric peak containing CDK2 protein (SDS-PAGE) was pooled and concentrated to 10 mg/ml.
Vapor diffusion crystallization was initiated using hanging drops made from 1 ul of protein and 1 ul of reservoir (20% PEG 4K, and 50 mM Hepes pH 7.5 and 50 mM ammonium acetate) and incubated at 19 °C. Crystal clusters grew overnight, and then were washed and crushed for use as seeds. A fresh hanging drop was set up by mixing 1 ul of protein and 1 ul of reservoir (10-12 % PEG 4K, 50 mM Hepes pH 7.5 and 50 mM ammonium acetate), and streak-seeded (Hampton Research). Single crystals grew overnight at 19 °C.
Compound 8 was added to CDK2 crystals by soaking. Several crystals were immersed in 10 ul of 10% PEG 4K, 50 mM Hepes pH 7.5, 50 mM ammonium acetate made 3 mM in compound 8 (and 6% DMSO) using a 50 mM DMSO stock solution. This droplet was maintained over a well containing 12% PEG 4K, 50 mM Hepes pH 7.5, 50 mM ammonium acetate overnight at 19 0 C.
Crystals were washed in 25% ethylene glycol, 10% PEG 4K, 50 mM Hepes pH 7.5 and 50 mM ammonium acetate and then preserved for data collection by immersion in liquid nitrogen.
Data collection, structure solution and refinement
Diffraction data were reduced using either HKL2000 2 or XDS 3 and elements of the CCP4 suite 4 .
Inhibitors were added using electron density maps after rigid-body refinement of template coordinate files from the PDB from which ligands, ions and solvent atoms had been stripped.
Model building was performed using Coot, inhibitor coordinate restraint parameters were generated using Corina (Molecular Networks), and crystallographic refinement and some water additions used REFMAC5 5 , Phenix.refine 6 and/or BUSTER. For CDK2/8, the "catalytic" Lysine residue (Lys33) is acetylated. Data reduction and final refinement statistics are in Table S4 .
